75 years of excellence Combination Products NEMA’s Comments for the Office of Combination Products Public Hearing Terry Sweeney, Philips Medical Systems.

Slides:



Advertisements
Similar presentations
Regulatory Pathway for Platform Technologies
Advertisements

Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Part 15 Public Hearing FDA Regulation of Combination Products November 25, 2002 Rockville, MD Michael Gross, Ph.D., RAC Vice-President Worldwide Compliance.
Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
Licensure Requirements for Cosmetic Laser Procedures By: Vickie L. Mickey, CT,CLHRP.
Amplatzer® Septal Occluder
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
FDA Perspective Sally Loewke, M.D. Acting Division Director
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Cross-Labeling: Legal and Regulatory Issues David M. Fox Hogan & Hartson LLP th Street, NW Washington, DC
21 CFR PART 11 REGULATIONS RECOMMENDATIONS FOR CHANGES FDA PUBLIC MEETING ON PART 11 REGULATIONS – JUNE 11, 2004 NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION.
Innovative Systems for Delivery of Drugs and Biologics Drug-Eluting Stents Current Approach to Review Ashley B. Boam, MSBE Division of Cardiovascular Devices.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Proprietary Names and the Drug Approval Process John K. Jenkins, M.D., F.C.C.P. Director, Officer of New Drugs Center for Drug Evaluation and Research.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.
Office of Combination Products: Current Initiatives
Serious adverse events following falsely high glucose measurements resulting from administration of an IGIV product containing maltose L. Ross Pierce,
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.
CASTRO VALLEY ADULT AND CAREER EDUCATION CMA PROGRAM FOOD AND DRUG ADMINISTRATION.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Cook Zenith® AAA Endovascular Graft and the H&L-B One-Shot  Introduction System P April 10, 2003 FDA Circulatory System Devices Panel Meeting Gaithersburg,
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
FDA Focus On Consumer Protection
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Drug - Device Combination Issues : Oncology Perspective Ramzi Dagher, M.D. DODP/CDER/FDA.
“513(g)s” Requests for Information Lawrence “Jake” Romanell, RM (AAM) Office of Device Evaluation Center for Devices and Radiological Health.
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
Overview of FDA's Regulatory Framework for PET Drugs
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
History of Pediatric Labeling
06/02/04DRAFT1. 06/02/04DRAFT2 QUESTIONS FOR PANEL Trial Design 1.The sponsor makes outcome comparisons between the selected subgroups of LVAS and control.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
Regulatory and Legal Challenges for Developers of Drug Delivery Devices Public Workshop: Innovative Systems for Delivery of Drugs.
FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
1 Cardiovascular and Renal Drugs Advisory Committee Questions June 24, 2008 Ira Krefting, MD.
Adverse Event Reporting for Combination Products Bradley Merrill Thompson Leighton Hansel Colleen Hittle.
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® Septal Occlusion System with Qwik Load NMT Medical P
COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.
Conclusion Senior Vice President Medical & Drug Regulatory Affairs Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut Manfred Haehl, MD.
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
The Regulation on Cell Therapy Products in Japan
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Clinical Review Process for New Drug Development and Application
GCP AND MEDICAL DEVICES
Regulatory Considerations for Coronary Drug Coated Balloons (DCBs)
Balancing Pre and Postmarket Requirements Different Scenarios
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
FDA-CDRH in the Next Decade A Vision for Change
Michael Gross, Ph.D., RAC Vice-President Worldwide Compliance
Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Presentation transcript:

75 years of excellence Combination Products NEMA’s Comments for the Office of Combination Products Public Hearing Terry Sweeney, Philips Medical Systems

75 years of excellence Question 2 Safety and Effectiveness should be considered on a component basis  Imaging Contrast Agent  Imaging Device (Magnetic Resonance, Ultrasound, etc.) Effectiveness should be delegated to the component with the Primary Function  Imaging system creates the image, Imaging system has the primary function.

75 years of excellence Question 2 - cont. Center with appropriate expertise in the primary function should lead the review of effectiveness  CDRH should be lead reviewer for effectiveness of imaging systems using contrast agents that have been approved for safety by CDER.

75 years of excellence Question 3 Use review process appropriate to the component  Contrast Agent: Drug safety: CDER New drug Revised dosing  Imaging Device: Imaging Efficacy: CDRH New indication Expanded indication

75 years of excellence Question 4 Use Application appropriate for the component  Contrast Agent: Drug Application processes NDA, aNDA  Imaging Device: Device application processes 510(k), PMA

75 years of excellence Question 5 Use Quality System appropriate for the component  Contrast Agent: cGMP  Imaging Device: QSR

75 years of excellence Question 6 Use adverse event reporting system appropriate for the cited component  Contrast Agent: Adverse Experience Reports  Imaging Device: Medical Device Reports (MDR)

75 years of excellence Question 7 Separate cross labeling requirements:  Use Least Burdensome provisions to set appropriate regulatory controls  Intended Use statements may be distinct based upon safety risk: Contra-indications may be applied to only one OR both components Cross-reference high-risk issues De-couple component-specific issues (i.e. effectiveness)

75 years of excellence Question 7 - cont.  Allow manufacturers of each component of a combination product to modify labeling in line with a high degree of patient protection Pharmacology: Agent manufacturer Imaging effectiveness: Device manufacturer  Allow Center with expertise in each component to review labeling for that component Contrast Agent: CDER Imaging Device: CDRH